photoaged skin Dihydromyricetin
Conditions
Interventions
Participants will receive topical serum containing Dihydromyricetin for application to the entire face and neck twice daily (morning and evening). The serum will be applied for a total duration of 8 w
Experimental Device
Treatment
Sponsors
Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand
Eligibility
Sex/Gender
All
Age
30 Years to 45 Years
Inclusion criteria
Inclusion criteria: 1. Aged 30-45 years, both male and female 2. Thai individuals of Asian ethnicity with Fitzpatrick skin type III-V 3. Voluntarily provide informed consent to participate in the study Assessed by a dermatologic surgery specialist and determined to have moderate or higher levels of photo-damaged skin on both the face and neck, according to the Glogau classification of photoaging
Exclusion criteria
Exclusion criteria: 1. Pregnant or breastfeeding women, determined by menstrual and contraception history (if pregnancy is suspected, a urine pregnancy test will be performed; individuals with a positive result or confirmed pregnancy will be excluded). 2. Participants with underlying disorders affecting collagen synthesis. 3. Participants with a known allergy to dihydromyricetin. 4. Participants who have used oral or topical whitening agents on the face or neck within 3 months prior to enrollment. 5. Participants who are taking oral antioxidant supplements. 6. Participants who smoke or have a history of heavy alcohol consumption. 7. Participants who have undergone facial or neck lifting procedures, including energy-based devices or thread lifts, within 6 months prior to the study. 8. Participants with a history of filler injections on the face or neck within 6 months prior to enrollment. 9. Participants with a history of platelet-rich plasma (PRP) injections on the face or neck within 6 months prior to enrollment. 10. Participants with a history of botulinum toxin injections on the face or neck within 6 months prior to enrollment. 11. Participants with a history of collagen-stimulating laser treatments on the face or neck, such as picosecond laser, Er:YAG laser, Fractora, or E-matrix, within 6 months prior to enrollment. 12. Participants with a history of keloid or hypertrophic scarring. 13. Participants with a history of hormonal therapy (topical, oral, injectable, or implant) within 6 months prior to enrollment. 14. Participants with a psychiatric disorder diagnosed by a psychiatrist. 15. Participants who do not consent to photographic documentation for treatment assessment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Lifting baseline, 4 weeks, 8 weeks, 12 weeks after complete treatment Vectra H2,Lifting baseline, 4 weeks, 8 weeks, 12 weeks after complete treatment Quantificare,Physician improvement scale baseline, 4 weeks, 8 weeks, 12 weeks after complete treatment percent improvement, Patient Improvement scale baseline, 4 weeks, 8 weeks, 12 weeks after complete treatment percent improvement,Safety baseline, 4 weeks, 8 weeks, 12 weeks after complete treatment Adverse event | — |
Secondary
| Measure | Time frame |
|---|---|
| Skin elasticity baseline, 4 weeks, 8 weeks, 12 weeks after complete treatment Cutometer,Skin firmness baseline, 4 weeks, 8 weeks, 12 weeks after complete treatment Cutometer,Melanin index baseline, 4 weeks, 8 weeks, 12 weeks after complete treatment Mexameter,Erythema index baseline, 4 weeks, 8 weeks, 12 weeks after complete treatment Mexameter,Hydration baseline, 4 weeks, 8 weeks, 12 weeks after complete treatment Corneometer,Transepidermal water loss baseline, 4 weeks, 8 weeks, 12 weeks after complete treatment Tewameter,Individual Typology Angle baseline, 4 weeks, 8 weeks, 12 weeks after complete treatment Colorimeter,Sebum level baseline, 4 weeks, 8 weeks, 12 weeks after complete treatment Sebumeter,UV spots baseline, 4 weeks, 8 weeks, 12 weeks after complete treatment Visia,Brown spots baseline, 4 weeks, 8 weeks, 12 weeks after complete treatment Visia,Red spots baseline, 4 weeks, 8 weeks, 12 weeks after complete treatment Visia,Pores baseline, 4 weeks, 8 weeks, 12 weeks after complete treatment Visia,Porphyrin baseline, 4 weeks, 8 weeks, 12 weeks after complete treatment Visia,Wrinkles baseline, 4 weeks, 8 weeks, 12 weeks after complete treatment Antera,Texture baseline, 4 weeks, 8 weeks, 12 weeks after complete treatment Antera,Volume depression baseline, 4 weeks, 8 weeks, 12 weeks after complete treatment Antera | — |
Countries
Thailand
Contacts
Public ContactRungsima Wanitphakdeedecha
Faculty of Medicine Siriraj Hospital, Mahidol University
Outcome results
None listed